UPSTREAM BIO, INC. Increase (Decrease) in Accounts Payable
UPSTREAM BIO, INC. (UPB) reported Increase (Decrease) in Accounts Payable of -$412.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-11
- UPSTREAM BIO, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $604.00K.
- UPSTREAM BIO, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$1.02M, a 242.90% decline year-over-year.
- UPSTREAM BIO, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$1.23M.
- UPSTREAM BIO, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $1.40M.
- UPSTREAM BIO, INC. increase (decrease) in accounts payable for fiscal 2025 was -$1.28M, a 163.51% decline from fiscal 2024.
- UPSTREAM BIO, INC. increase (decrease) in accounts payable for fiscal 2024 was $2.02M, a 57.82% increase from fiscal 2023.
- UPSTREAM BIO, INC. increase (decrease) in accounts payable for fiscal 2023 was $1.28M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $604.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$412.00K 10-Q · filed 2026-08-11 | -$1.64M derived: sum of 3 quarters · filed 2026-08-11 | -$237.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$1.02M 10-Q · filed 2026-05-13 | -$2.24M derived: sum of 2 quarters · filed 2026-05-13 | -$841.00K derived: sum of 3 quarters · filed 2026-05-13 | -$3.01M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $175.00K derived: sum of 2 quarters · filed 2026-03-26 | -$1.99M derived: sum of 3 quarters · filed 2026-08-11 | -$1.28M 10-K · filed 2026-03-26 |
| 2025-09-30 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$766.00K derived: sum of 2 quarters · filed 2026-08-11 | -$55.00K 10-Q · filed 2025-11-05 | -$926.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$2.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.46M 10-Q · filed 2026-08-11 | -$2.33M derived: sum of 3 quarters · filed 2026-08-11 | -$2.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $711.00K 10-Q · filed 2026-05-13 | -$160.00K derived: sum of 2 quarters · filed 2026-05-13 | -$334.00K derived: sum of 3 quarters · filed 2026-05-13 | $3.34M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$871.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$1.04M derived: sum of 2 quarters · filed 2026-03-26 | $2.63M derived: sum of 3 quarters · filed 2026-03-26 | $2.02M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$174.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.50M derived: sum of 2 quarters · filed 2025-11-05 | $2.89M 10-Q · filed 2025-11-05 | $4.64M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $3.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $3.06M 10-Q · filed 2025-08-06 | $4.82M derived: sum of 3 quarters · filed 2025-08-06 | |
| 2024-03-31 | -$615.00K 10-Q · filed 2025-05-06 | $1.14M derived: sum of 2 quarters · filed 2025-05-06 | ||
| 2023-12-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $1.28M 10-K · filed 2025-03-12 | ||
| 2023-09-30 | -$479.00K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |